GSK’s Blood Cancer Drug Fails Main Goal of Trial, Shares Fall

GSK’s Blood Cancer Drug Fails Main Goal of Trial, Shares Fall
GSK (GlaxoSmithKline) logo on Aug. 10, 2022. Dado Ruvic/Illustration/Reuters
Reuters
Updated:

GSK’s blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market, the company said on Monday.

Oncology is a key area of focus for GSK as a standalone prescription medicine and vaccine business and its shares fell 3 percent after its statement, which raised concerns that regulatory approval of Blenrep may be rescinded.